NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lifordi Immunotherapeutics' Strategic Investment and LFD-200 Clinical Development
TL;DR
Lifordi's $112 million funding from Sanofi Ventures and others provides a strategic advantage in advancing LFD-200, potentially capturing the autoimmune treatment market with targeted ADC technology.
Lifordi's LFD-200 delivers glucocorticoids directly to immune cells via antibody-drug conjugates, using VISTA targeting to maintain efficacy while limiting systemic toxicity through precise cellular delivery.
Lifordi's targeted ADC approach could revolutionize autoimmune disease treatment by enabling safe, long-term glucocorticoid use, improving quality of life for millions suffering from chronic inflammatory conditions.
Lifordi's novel ADC platform delivers glucocorticoids directly to immune cells, potentially solving a 75-year toxicity problem that has limited steroid treatments for autoimmune diseases.
Found this article helpful?
Share it with your network and spread the knowledge!
Lifordi Immunotherapeutics has secured a strategic investment from Sanofi Ventures and additional funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture, bringing total funding to $112 million to support their Phase 1 clinical trial of LFD-200 for rheumatoid arthritis.
LFD-200 is an antibody-drug conjugate (ADC) that delivers a potent glucocorticoid directly to immune cells and is being developed for the treatment of rheumatoid arthritis and other autoimmune and inflammatory disorders.
The investment provides crucial funding to advance the Phase 1 clinical trial, supports Chemistry Manufacturing and Controls preparations for Phase 2 clinical supply, and brings strategic expertise from Sanofi Ventures through board representation.
LFD-200 is currently in a Phase 1 clinical trial that is enrolling and dosing healthy participants, with initial data from healthy participants expected in the coming months, followed by planned evaluation in patients with moderate to severe rheumatoid arthritis.
LFD-200 uses targeted ADC technology to deliver glucocorticoids directly to immune cells, harnessing their efficacy while limiting systemic toxicity, potentially solving the problem that has limited broad and long-term use of glucocorticoids for the past 75 years.
The investment includes Sanofi Ventures as a new strategic investor, along with continued support from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture.
Christopher Gagliardi, Ph.D., Principal at Sanofi Ventures, will join as an observer on Lifordi's Board of Directors, enabling Sanofi to share expertise and experiences to help guide LFD-200 through clinical studies.
Non-clinical data presented at the American College of Rheumatology 2025 meeting showed that clinically relevant doses of LFD-200 given subcutaneously every 7 days for 13 weeks maintained glucocorticoid exposure in immune cells without evidence of systemic toxicity in multiple animal models of autoimmune disease.
Lifordi has applied its novel drug delivery platform to other diverse payloads, such as ASOs or siRNAs, indicating potential for delivering various therapeutic agents using their targeted ADC approach.
Initial data from healthy participants in the Phase 1 study is expected to be shared in the coming months, following single and multiple ascending dosing studies.
Curated from Reportable
